Shares of NanoString Technologies, Inc. (NASDAQ:NSTG) have received an average recommendation of “Hold” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $20.00.

A number of research firms have issued reports on NSTG. Zacks Investment Research lowered shares of NanoString Technologies from a “buy” rating to a “sell” rating in a research note on Thursday, July 6th. Morgan Stanley lowered shares of NanoString Technologies from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $23.00 to $20.00 in a research note on Thursday, April 20th. ValuEngine raised shares of NanoString Technologies from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cowen and Company reissued a “buy” rating on shares of NanoString Technologies in a research note on Friday. Finally, BidaskClub lowered shares of NanoString Technologies from a “hold” rating to a “sell” rating in a research note on Sunday.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. American International Group Inc. raised its position in NanoString Technologies by 7.4% in the first quarter. American International Group Inc. now owns 9,153 shares of the biotechnology company’s stock worth $182,000 after buying an additional 634 shares during the last quarter. Strs Ohio raised its position in NanoString Technologies by 4.2% in the first quarter. Strs Ohio now owns 32,600 shares of the biotechnology company’s stock worth $647,000 after buying an additional 1,300 shares during the last quarter. Teachers Advisors LLC raised its position in NanoString Technologies by 7.1% in the fourth quarter. Teachers Advisors LLC now owns 23,597 shares of the biotechnology company’s stock worth $526,000 after buying an additional 1,557 shares during the last quarter. Bank of America Corp DE raised its position in NanoString Technologies by 16.6% in the first quarter. Bank of America Corp DE now owns 11,404 shares of the biotechnology company’s stock worth $227,000 after buying an additional 1,627 shares during the last quarter. Finally, Columbus Circle Investors raised its position in NanoString Technologies by 27.1% in the first quarter. Columbus Circle Investors now owns 31,181 shares of the biotechnology company’s stock worth $620,000 after buying an additional 6,649 shares during the last quarter. 87.10% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/17/nanostring-technologies-inc-nasdaqnstg-given-average-recommendation-of-hold-by-brokerages.html.

NanoString Technologies (NSTG) traded up 0.37% on Monday, reaching $16.17. 35,283 shares of the company traded hands. The company has a 50-day moving average price of $17.03 and a 200-day moving average price of $18.73. NanoString Technologies has a 12 month low of $13.06 and a 12 month high of $23.45. The company’s market capitalization is $350.73 million.

NanoString Technologies (NASDAQ:NSTG) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.87) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.87). NanoString Technologies had a negative net margin of 57.13% and a negative return on equity of 6,777.29%. The business had revenue of $18.10 million during the quarter, compared to analyst estimates of $17.53 million. During the same period in the previous year, the business posted ($0.74) EPS. The company’s quarterly revenue was up 23.1% on a year-over-year basis. Equities research analysts expect that NanoString Technologies will post ($2.56) EPS for the current year.

NanoString Technologies Company Profile

NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

Receive News & Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.